Eslami-Arshaghi Tarlan, Salehi Mohammad, Soleimani Masoud, Gholipourmalekabadi Mazaher, Mossahebi-Mohammadi Majid, Ardeshirylajimi Abdolreza, Rajabi Hoda
Department of Transgenic Animal Sciences, Stem Cells Technology Research Center, Tehran, Iran.
Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Biotechnology Department, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Biologicals. 2015 Sep;43(5):349-54. doi: 10.1016/j.biologicals.2015.07.001. Epub 2015 Aug 1.
Stem cells therapy is considered as an efficient strategy for the treatment of some diseases. Nevertheless, some obstacles such as probability of rejection by the immune system limit applications of this strategy. Therefore, several efforts have been made to overcome this among which using the induced pluripotent stem cells (iPSCs) and nuclear transfer embryonic stem cell (nt-ESCs) are the most efficient strategies. The objective of this study was to evaluate the differentiation potential of the nt-ESCs to lymphoid lineage in the presence of IL-7, IL-3, FLT3-ligand and TPO growth factors in vitro. To this end, the nt-ESCs cells were prepared and treated with aforementioned growth factors for 7 and 14 days. Then, the cells were examined for expression of lymphoid markers (CD3, CD25, CD127 and CD19) by quantitative PCR (q-PCR) and flow cytometry. An increased expression of CD19 and CD25 markers was observed in the treated cells compared with the negative control samples by day 7. After 14 days, the expression level of all the tested CD markers significantly increased in the treated groups in comparison with the control. The current study reveals the potential of the nt-ESCs in differentiation to lymphoid lineage in the presence of defined growth factors.
干细胞疗法被认为是治疗某些疾病的有效策略。然而，一些障碍，如被免疫系统排斥的可能性，限制了该策略的应用。因此，人们已经做出了一些努力来克服这一问题，其中使用诱导多能干细胞（iPSC）和核移植胚胎干细胞（nt-ESC）是最有效的策略。本研究的目的是在体外白细胞介素-7（IL-7）、白细胞介素-3（IL-3）、fms样酪氨酸激酶3配体（FLT3-ligand）和血小板生成素（TPO）生长因子存在的情况下，评估nt-ESC向淋巴谱系的分化潜能。为此，制备了nt-ESC细胞，并用上述生长因子处理7天和14天。然后，通过定量聚合酶链反应（q-PCR）和流式细胞术检测细胞中淋巴标志物（CD3、CD25、CD127和CD19）的表达。与阴性对照样品相比，在第7天时，处理后的细胞中CD19和CD25标志物的表达增加。14天后，与对照组相比，处理组中所有检测的CD标志物的表达水平均显著增加。当前研究揭示了在特定生长因子存在的情况下，nt-ESC向淋巴谱系分化的潜能。
